Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Frontier Capital Management Co. LLC

Frontier Capital Management Co. LLC lowered its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 61.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 150,172 shares of the company’s stock after selling 242,091 shares during the quarter. Frontier Capital Management Co. LLC owned 0.23% of Kymera Therapeutics worth $6,041,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of KYMR. Franklin Resources Inc. increased its position in shares of Kymera Therapeutics by 35.1% in the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock valued at $1,356,000 after purchasing an additional 7,647 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock valued at $6,649,000 after buying an additional 95,547 shares during the last quarter. Harbor Capital Advisors Inc. raised its stake in Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after buying an additional 684 shares in the last quarter. Blue Trust Inc. lifted its holdings in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after acquiring an additional 752 shares in the last quarter.

Analyst Upgrades and Downgrades

KYMR has been the subject of several research analyst reports. Stephens restated an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. HC Wainwright raised their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Citigroup assumed coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a “buy” rating and a $52.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $56.36.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the transaction, the chief financial officer now owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by company insiders.

Kymera Therapeutics Stock Down 2.3 %

Shares of KYMR stock opened at $30.07 on Friday. The stock has a 50-day simple moving average of $29.57 and a 200 day simple moving average of $37.67. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The stock has a market capitalization of $1.96 billion, a P/E ratio of -12.85 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same period last year, the company earned ($0.69) earnings per share. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.